Vividion Therapeutics, Inc.
5820 Nancy Ridge Drive
About Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the limitless creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. Founded in 2016, the company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. For more information, please visit www.vividion.com.
CEO: Jeffrey S. Hatfield
CBO/President: Fred Aslan, M.D.
CSO: Bob Abraham, Ph.D.
Benjamin F. Cravatt, Ph.D.
Phil S. Baran, Ph.D.
Jin-Quan Yu, Ph.D.
30 articles with Vividion Therapeutics, Inc.
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry
Vividion Therapeutics today announced the appointments of Fred Aslan, M.D. as President and Chief Business Officer and Larry Burgess, Ph.D. as Head of Chemistry.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases.
Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies.
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
Vividion Therapeutics, Inc. announced a strategic research collaboration with Celgene Corporation.